1. |
Mok T, Wu YL, Zhang L. A small step towards personalized medicine for non-small cell lung cancer [J]. Discov Med, 2009; 8(43): 227-231.
|
2. |
Chu Q, Amano O, Kanda Y, et al. Tumor-specific Cytotoxicity and Type of Cell Death Induced by Gefitinib in Oral Squamous Cell Carcinoma Cell Lines [J]. Anticancer Res, 2009; 29(12): 5023-5031.
|
3. |
Yang CT, Hung JY, Lai CL, et al. Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in Southern Taiwan [J]. Kaohsiung J Med Sci, 2010; 26(1): 1-7.
|
4. |
Herbst RS, Fukuoka M, Baselga J. Gefitinib-a novel targeted approach to treating cancer [J]. Nat Rev Cancer, 2004; 4(12): 956-965.
|
5. |
Yoon JH, Gwak GY, Lee HS, et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells [J]. J Hepatol, 2004; 41(5): 808-814.
|
6. |
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 1 [J]. J Clin Oncol, 2004; 22(5): 777-784.
|
7. |
Hwang JH, Yoon YB, Kim YT, et al. Risk factors for recurrent cholangitis after initial hepatolithiasis treatment [J]. J Clin Gastroenterol, 2004; 38(4): 364-367.
|
8. |
Terada T, Nakanuma Y. Pathologic observations of intrahepatic peribiliary glands in 1 000 consecutive autopsy livers: Ⅳ. Hyperplasia of intramural and extramural glands [J]. Hum Pathol, 1992; 23(5): 483-490.
|
9. |
Terada T, Nakanuma Y. Innervation of intrahepatic bile ducts and peribiliary glands in normal human livers, extrahepatic biliary obstruction and hepatolithiasis. An immunohistochemical study [J]. J Hepatol, 1989; 9(2): 141-148.
|
10. |
Lu S, Yan L, Rao L, Xia T, et al. Down stream involvement of the bile duct in hepatolithiasis [J]. Chin Med J (Engl), 2002; 115(1): 62-64.
|
11. |
Uchiyama K, Kawai M, Ueno M, et al. Reducing residual and recurrent stones by hepatectomy for hepatolithiasis [J]. J Gastrointest Surg, 2007; 11(5): 626-630.
|
12. |
货师鹏. 受体研究技术 [M]. 北京: 北京大学医学出版社, 2004: 275-277.
|
13. |
Schlessinger J. Cell signaling by receptor tyrosine kinases [J]. Cell, 2000; 103(2): 211-225.
|
14. |
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network [J]. Nat Rev Mol Cell Biol, 2001; 2(2): 127-137.
|
15. |
Hackel PO, Zwick E, Prenzel N, et al. Epidermal growth factor receptors: critical mediators of multiple receptor pathways [J]. Curr Opin Cell Biol, 1999; 11(2): 184-189.
|
16. |
Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGF-receptor [J]. Curr Opin Cell Biol, 1999; 11(2): 190-196.
|
17. |
Ishii M, Vroman B, LaRusso NF. Morphologic demonstration of receptor-mediated endocytosis of epidermal growth factor by isolated bile duct epithelial cells [J]. Gastroenterology, 1990; 98(5 Pt 1): 1284-1291.
|
18. |
Van Winkle LS, Isaac JM, Plopper CG. Distribution of epidermal growth factor receptor and ligands during bronchiolar epithelial repair from naphthalene-induced Clara cell injury in the mouse [J]. Am J Pathol, 1997; 151(2): 443-459.
|
19. |
Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy [J]. Ann Oncol, 2005; 16(4): 538-548.
|
20. |
Hamdi MM, Mutungi GM. Dihydrotestosterone activates the mitogen activated protein kinase pathway and modulates maximum isometric force in isolated intact mouse skeletal muscle fibres through the epidermal growth factor receptor [J]. J Physiol [Epub ahead of print]. PMID: 20008468. doi: 10.1113/jphysiol.2009.182162.
|
21. |
Kondratov KA, Chernorudskiy AL, Amosova AP, et al. Termination of tyrphostin AG1478 application results in different recovery of EGF receptor tyrosine residues 1 045 and 1 173 phosphorylation in A431 cells [J]. Cell Biol Int, 2010; 34(1): 81-87.
|
22. |
Donnellan F, Keating N, Geoghegan P, et al. JNK mitogen-activated protein kinase limits calcium-dependent chloride secretion across colonic epithelial cells [J]. Am J Physiol Gastrointest Liver Physiol, 2009 Oct 29[Epub ahead of print]. PMID: 19875701.
|
23. |
正文, 朱明才, 汤为学, 等. 金雀异黄素与5-氟尿嘧啶对SGC-7901 细胞的抑制作用 [J]. 中国普外基础与临床杂志, 2008; 15(1): 17-22.
|
24. |
李龙, 岳红梅, 余勤. 表皮生长因子受体抑制剂与肺纤维化 [J]. 国外医学呼吸系统分册, 2005; 25(5): 345-348.
|
25. |
龙怀聪, 王曾礼. 表皮生长因子受体拮抗剂对气道上皮细胞生长及修复的影响 [J]. 四川大学学报(医学版), 2003; 34(2): 254-256.
|
26. |
Fan ST, Choi TK, Lo CM, et al. Treatment of hepatolithiasis: improvement of result by a systematic approach [J]. Surgery, 1991; 109(4): 474-480.
|
27. |
Douillard JY, Kim E, Hirsh V, et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02 [J]. J Thorac Oncol, 2007; 2(8): S305-S306.doi: 10.1097/01.JTO.0000283087.71346.19.
|
28. |
Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy [J]. Drugs, 2000; 60 Suppl 1: 15-23.
|
29. |
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) [J]. Lancet, 2005; 366(9496): 1527-1537.
|
30. |
Oguey D, Marti U, Reichen J. Epidermal growth factor receptor in chronic bile duct obstructed rats: implications for maintenance of hepatocellular mass [J]. Eur J Cell Biol, 1992; 59(1): 187-195.
|
31. |
Matsumoto K, Fujii H, Michalopoulos G, et al. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro [J]. Hepatology, 1994; 20(2): 376-368.
|